Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” The once-daily oral small molecule APOL1 inhibitor, ...

Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host ...

The American Association of Clinical Endocrinology (AACE) has released the 2026 update to its consensus statement algorithm for the management of adults with type 2 diabetes (T2D). The statement was ...

There was an error while loading. Please reload this page.